Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
iOnctura
OncoNano Medicine, Inc.
Mayo Clinic
City of Hope Medical Center
Bio-Path Holdings, Inc.
City of Hope Medical Center
Celldex Therapeutics
Stanford University
Stanford University
NovalGen Ltd.
Seagen Inc.
Opna Bio LLC
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Jonsson Comprehensive Cancer Center
Pfizer
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
University of Wisconsin, Madison
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
University of California, San Francisco
National Cancer Institute (NCI)
Massachusetts General Hospital
University of Louisville
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Progen Pharmaceuticals
Morphotek
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
National Cancer Institute (NCI)
Indiana University
Indiana University
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute